Startups
2008
ARGON PHARMA SLDevelopment of antitumoural drugs and biodegradable polymeric nanocarriers, for applications in imaging diagnosis markers and antitumoural drugs release.
Address
Carrer de Baldiri Reixac 15, 08028 Barcelona, Spain
CERCA ownership
Barcelona, Spain
1992
Institut de Recerca Sant Pau
Other Catalan Public owners
Logo
Status & Deeptech areas
Company Status & Company Deeptech AreasCurrent company status
DeepTech Area
Spinoff information
Company Description
Development of antitumoural drugs and biodegradable polymeric nanocarriers, for applications in imaging diagnosis markers and antitumoural drugs release.
Product description
Linear α-polyglutamic acid polymer (PGA) with low polydispersity (1,1-1.2) up to MW 150 KDa.
Drug development areas
Antitumoural drugs: Argon Pharma is developing drugs aimed at treating cancer.
Drug delivery systems: The company develops biodegradable polymeric nanocarriers that can be used to release drugs or as imaging diagnosis markers.
Specific drug programs:
Oncostane: An oral drug specifically for pancreatic cancer, which has completed some preclinical trials.
Glioblastoma drug: Through a partnership with SOM Biotech, Argon Pharma is developing a molecule that is an inhibitor of focal adhesions, with potential applications for treating glioblastoma and other cancers.
Drug development areas
Antitumoural drugs: Argon Pharma is developing drugs aimed at treating cancer.
Drug delivery systems: The company develops biodegradable polymeric nanocarriers that can be used to release drugs or as imaging diagnosis markers.
Specific drug programs:
Oncostane: An oral drug specifically for pancreatic cancer, which has completed some preclinical trials.
Glioblastoma drug: Through a partnership with SOM Biotech, Argon Pharma is developing a molecule that is an inhibitor of focal adhesions, with potential applications for treating glioblastoma and other cancers.
Company Closed or Exit Year